News

The company’s loss from operations for the second quarter of 2011 was $364,000, compared to $1.97m for the same period in 2010. For the six months ended 30

COTI-2 uses the company’s proprietary artificial intelligence system – Chemsas which uses a series of predictive computer models to identify compounds integrated in disease-specific drug discovery. COTI-2 inhibits

The deal covers Yemen, Syria, Tunisia, Sudan, Morocco, South Sudan, Jordan, Lebanon Libya, Algeria, Iraq and Egypt. Further details of the agreement were not disclosed. Hikma Pharma CEO

The study is intended to evaluate CUDC-101 when administered concurrently with radiation and cisplatin in human papillomavirus negative (HPV-) locally advanced head and neck cancer patients. The company

Egrifta, a once-daily injection, is a novel, stabilized analogue of GRF. GRF is a hypothalamic peptide that acts on the pituitary cells in the brain to stimulate the

PAA Laboratories is a developer and manufacturer of specialized and cell culture products such as media, sera, growth supplements and reagents for use in biomedical research and in

The colon-screen will use Phloral coating technology to deliver the drug to the target site by applying two mechanisms to trigger drug release. The mechanism is based on

Eylea is indicated as a treatment for neovascular age-related macular degeneration (wet AMD). The extension of three months follows the recent amendment made by the company on the

The collaboration allows HGS to develop 4-Antibody’s proprietary in vitro Retrocyte Display technology (Retroviral B lymphocyte Display) to discover sources for antibody drug candidates. Retrocyte Display creates therapeutic